Liquid CO2 Assay Improved on Clinical Chemistry Analyzers
By LabMedica International staff writers
Posted on 31 Jul 2009
A new kit for measuring liquid CO2 in plasma and serum has been developed and improved for use on clinical chemistry analyzers. Posted on 31 Jul 2009
The improvement in CO2 measurement includes improved linearity and correlation with other current assays. The RX series of clinical chemistry analyzers offer time, labor, and cost savings, ensuring efficient and accurate laboratory testing.
Randox (Crumlin, UK) announced an important improvement in liquid CO2 measurement in serum and plasma on the company's RX series of clinical chemical analyzers. The improved reagent stability for onboard use, calibration, and shelf life make it much easier to measure the levels of CO2 in patient samples.
Carbon dioxide levels are regulated by the kidneys, with extreme levels indicating difficulty regulating pH. Elevated levels may be evident in chronic lung problems such as emphysema, whereas low levels can be seen in states of shock, starvation, kidney failure, or chronic diarrhea.
A metabolic waste product of cellular respiration, elevated levels of CO2 in the blood occur in hypercapnia and respiratory acidosis. CO2 levels rise with decreased alveolar ventilation due to diseases of the lungs or bronchial tree, or breathing CO2-enriched air. Depression of the overall lung capacity by certain drugs may lead to retention of CO2.
Randox is an international diagnostics company, headquartered in the UK. The company develops, manufactures, and markets clinical diagnostic products worldwide. Its core products include biochip array technology; clinical chemistry analyzers and reagents; quality controls; recombinant proteins and antibodies.
Related Links:
Randox